Professor of Surgery
University of Michigan
Vascular Staff
University of Michigan
Ann Arbor, Michigan
Presenter
SESSION 30: NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
Session Moderator
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Presenter
SESSION 93: BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS
Presenter
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Presenter
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
SESSION 30: NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)
When And Why Is ALI Best Treated By Open Surgery: When Are Endovascular Treatments Best
5:04 PM - 5:09 PM
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN
Postop Myocardial Infarctions (MIs) In Vascular Patients: What Are The New Options For Diagnosis, Prevention And Treatment
6:40 AM - 6:45 AM
Session Moderator
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Presenter
SESSION 93: BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS
Current Optimal Antiplatelet And Anticoagulation Treatment For Various Vascular Procedures In Various Vascular Beds: What Newer Drugs And DOACs Are Useful And What Is The Optimal Timing Of Treatment
3:06 PM - 3:11 PM
Presenter
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Update On Experimental DVT Vein Wall Injury
10:23 AM - 10:28 AM
Presenter
SESSION 98: VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES
Why Do VTE Risk Scores Fail To Prevent VTE
10:41 AM - 10:46 AM